Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Marts 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #755

    @ Solsen - lets hope we can get a similar article on CAR-T targeting BCMA, that would put me more at ease...

    1 Reply Last reply
    0
    • M Offline
      M Offline
      mobbyduck1
      wrote on sidst redigeret af
      #756

      @hda, ja Q1 med ROW tal der inkluderer fuldt 3 mdr salg i JApan, 4 linje i UK, samt Canada, det skal nok give lidt ekstra
      i kassen

      1 Reply Last reply
      0
      • H Offline
        H Offline
        hda
        wrote on sidst redigeret af
        #757

        Lige præcis mobbyduck1. Første gang vi får Japan med for hele kvartalet

        1 Reply Last reply
        0
        • A Offline
          A Offline
          AaBforever
          wrote on sidst redigeret af
          #758

          Ja det bliver spændende 17. april.

          1 Reply Last reply
          0
          • A Offline
            A Offline
            AaBforever
            wrote on sidst redigeret af
            #759

            Hvor langt vi kommer over 400 mill. i Q1

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #760

              after reaching €50mio, Dara lost Orphan status in Germany, leading to "eine Bekanntmachung" from the "Bundesministerium für Gesundheit" 😉 https://www.bundesanzeiger.de/ebanzwww/wexsservlet?session.sessionid=16a142094cdbe8edd5841e4fa803c0b8&page.navid=detailsearchlisttodetailsearchdetail&fts_search_list.selected=d747026b6b3fc404&fts_search_list.destHistoryId=16642 https://www.g-ba.de/informationen/nutzenbewertung/307/#tab/beschluesse

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #761

                pdf https://www.g-ba.de/downloads/39-261-3222/2018-02-15_AM-RL_XII_Daratumumab_D-310_BAnz.pdf

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #762

                  not sure if it has any further practical implications , but the document shows a good insight in costs for the different combinations, eg Dara Len Dex 246.965,89 €, vs Dara Bor Dex 185.522,46 € "

                  1 Reply Last reply
                  0
                  • H Offline
                    H Offline
                    hda
                    wrote on sidst redigeret af
                    #763

                    Ekstra Bladet om Darzalex salget i US i februar http://borsen.dk/nyheder/virksomheder/artikel/1/360281/genmab_darzalex-salget_faldt_i_usa_i_februar.html?utm_source=forside&utm_campaign=nyhed_03

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #764

                      Solsen, har du kendskab til et sammenligningsgrundlag for OS i ALL? 12,9 mdr. lyder ikke af meget, men spm er hvad man har opnået med andre midler.

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #765

                        ALL er vist ret aggressiv - her Blincito data ved godkendelse. Ved ikke om patientgrundlaget er det samme:

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #766

                          Document Moved

                          favicon

                          (www.amgen.com)

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #767

                            The approval is based on results from the TOWER study, which found that BLINCYTO demonstrated a superior improvement in median OS over standard of care (SOC) chemotherapy, nearly doubling median OS. The study showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO versus four months (95 percent CI: 2.9, 5.3) for SOC (hazard ratio for death=0.71; p=0.012). The approval is also based on data from the Phase 2 ALCANTARA study, which evaluated the efficacy of BLINCYTO in adult pat

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #768

                              Blincyto er CD19/CD3 så nok noget nær bedste sammenligning

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #769

                                with Ph+ relapsed or refractory B-cell precursor ALL.

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sibelius
                                  wrote on sidst redigeret af
                                  #770

                                  TIlgengæld skriver Berlingske i dag i ena rtikel om stigende udgifter til ny medicin i DK at omkostningerne til Darzalex steg mere end 500% fra 2016 til 2017. Der blev købt for DKK 138 millioner i 2017.

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #771

                                    Ja, det ville have været rart med en kontrolgruppe, der fik SOC i car-t studiet. Ved du hvad det der Philadelphia chromosome-negative-halløj indebærer? Er de hårdere ramt i Blincytostudiet?

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #772

                                      Ved det ikke Bulder, men umiddelbart vil jeg tro at de er hårdere ramt, men har som sagt intet at have det i

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #773

                                        Tak

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #774

                                          Man skal være opmærksom på, at ALL CAR-T studiet rekrutterede omkirng 90 pts og de har kun samlet data på 53 pts. Så en hel del pts er udgået ?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger